Last reviewed · How we verify
NCT05024786
The Effect of CQI on the Outcome of Patients Supported With ECMO
trial testing continuous quality improvements in Respiratory and Circulation Failure in 163 participants. Completed in 30 June 2021.
30 June 2021
Quick facts
| Lead sponsor | The Affiliated Hospital of Qingdao University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 163 |
| Start date | 1 July 2019 |
| Primary completion | 30 June 2021 |
| Estimated completion | 30 June 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- continuous quality improvements
Conditions studied
- Respiratory and Circulation Failure — all drugs for Respiratory and Circulation Failure →
Sponsor
The Affiliated Hospital of Qingdao University
Who can join
18 and older, any sex, with Respiratory and Circulation Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This was a prospective observational study in comparison with a retrospective control group(Jan 2015 to Jun 2019). Two ICUs in China were included. The continuous quality improvement (CQI)strategies were implemented from Jul 2019 to Jun 2021(CQI group). The mortalities of ECMO patients was compared between the CQI group and the control group.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A phased intervention bundle to decrease the mortality of patients with extracorporeal membrane oxygenation in intensive care unit.
Jing Y, Yuan Z, Zhou W, Han X, et al · · 2022 · cited 8× · PMID 36325385 · DOI 10.3389/fmed.2022.1005162
Verify or expand the search:
- PubMed search for NCT05024786
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The Affiliated Hospital of Qingdao University trials
Trials by the same sponsor.
- NCT07485920 — A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedani · Phase 4 · not yet recruiting
- NCT07465861 — Bed Rest Duration and Outcomes in Endoscopic Skull Base Reconstruction · NA · not yet recruiting
- NCT07453771 — Safety and Efficacy of Small Extracellular Vesicles Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma · NA · not yet recruiting
- NCT07404709 — Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Ste · Phase 1, PHASE2 · not yet recruiting
- NCT07167342 — The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05024786 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of Qingdao University
- Last refreshed: 27 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05024786.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing